Incyte (INCY) shares soared 5.5% in the last trading session to close at $102.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...
Incyte INCY announced that the European Commission (EC) has approved a label expansion of Minjuvi (tafasitamab). The drug, in combination with Revlimid (lenalidomide) and rituximab, is now indicated ...
Hosted on MSN
Mizuho upgrades Incyte (INCY)
Fintel reports that on December 8, 2025, Mizuho upgraded their outlook for Incyte (NasdaqGS:INCY) from Neutral to Outperform. Analyst Price Forecast Suggests 6.11% Downside As of December 6, 2025, the ...
Barclays analyst Etzer Darout maintained a Buy rating on Incyte today and set a price target of $115.00. Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Incyte Corporation is one of them. Incyte Corporation (NASDAQ:INCY), a global biopharmaceutical ...
We recently published 11 Best Cancer Stocks to Buy Right Now. Incyte Corporation stands fourth on our list. Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on cancer and ...
As one of the greatest superheroes in comic book history, Spider-Man has gotten the movie treatment many times in the past half-century. A total of 23 movies featuring the web-slinging hero and ...
Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback